Eplontersen sodium
依普隆特生钠Ligand-conjugated antisense therapy newly added to the 2026 Commercial Health Insurance Innovative Drug List (#24) for adult hereditary ATTR polyneuropathy.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字HJ20250151
- Initial Approval Date
- Dec 22, 2025
- Notice Published
- Dec 22, 2025
- MAH
- AstraZeneca AB (阿斯利康)
- Approved Scope
- Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #24 · 万诺维
- Validity Period
- 2027-01-01 to 2028-12-31
- MAH / Authorized Entity
- AstraZeneca AB · 阿斯利康(无锡)贸易有限公司
- Listed Indication Scope
- Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字HJ20250151 | Injection (注射液) | Initial Approval Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients. 适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。 | Approved: 2025-12-22 Published: 2025-12-22 | AstraZeneca AB |
Change Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Newly Added (#24)
Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Chinese original: 本品适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。
NHSA · PDF p.4Verified 2026-11-20 - (2025-12-22)NMPA Approval
NMPA Initial Marketing Approval (国药准字HJ20250151)
Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients.
Chinese original: 适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。
NMPA · NMPA Registration HJ20250151Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20